💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Pumactant

CHEMBL2108765 Phase 4 承認済み Unknown
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Pumactant (artificial lung expanding compound, ALEC) is a synthetic pulmonary surfactant composed of dipalmitoylphosphatidylcholine (DPPC) and phosphatidylglycerol that reduces alveolar surface tension, prevents alveolar collapse during expiration, and improves lung compliance in premature neonates. It was used for the prevention and treatment of neonatal respiratory distress syndrome (RDS), though it has been largely superseded by natural surfactant preparations.

作用機序

Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Pumactant (artificial lung expanding compound, ALEC) is a synthetic pulmonary surfactant composed of dipalmitoylphosphatidylcholine (DPPC) and phosphatidylglycerol that reduces alveolar surface tension, prevents alveolar collapse during expiration, and improves lung compliance in premature neonates. It was used for the prevention and treatment of neonatal respiratory distress syndrome (RDS), though it has been largely superseded by natural surfactant preparations.

Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.

Yes, Pumactant is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108765. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.